Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotest Pharmaceuticals (BPC), a wholly owned US subsidiary of Biotest, and ADMA Biologics have signed a strategic long-term manufacturing, supply and licensing deal.
Subscribe to our email newsletter
According to the deal, BPC will provide manufacturing services and license proprietary fractionation and purification manufacturing process for Respiratory Syncytial Virus (RSV) intravenous immune globulin to ADMA.
BPC chief executive officer Jordan Siegel said, "We are very pleased to partner with ADMA on their lead product candidate. Our ability to provide specialized contract manufacturing services will enable us to diversify our future revenue sources."
Under the agreement with an initial term of ten years, ADMA will make an initial payment for services provided in addition to percentage royalty on product revenues up to a specified maximum.